

***In re National Prescription Opiate Litigation: MDL No. 2804***  
**GENERIC MANUFACTURERS’**  
**MOTION FOR PARTIAL SUMMARY JUDGMENT**

**Summary Sheet of Exhibits**

<b>Ex.</b>	<b>Document Description</b>
1	Meredith Rosenthal, May 4, 2019 Dep.
2	FDA, “Generic Drugs Undergo Rigorous FDA Scrutiny,” available at <a href="https://www.fda.gov/consumers/consumer-updates/generic-drugs-undergo-rigorous-fda-scrutiny">https://www.fda.gov/consumers/consumer-updates/generic-drugs-undergo-rigorous-fda-scrutiny</a>
3	Karen A. Goldman et al., “Authorized Generic Drugs: Short-Term Effects and Long-Term Impact,” Federal Trade Commission Report, August 2011
4	Declaration of David Myers
5	Excerpt of Douglas Boothe, Jan. 17, 2019 Dep.
6	Excerpt of Michael Perfetto, Dec. 18, 2018 Dep.
7	Excerpt of David Myers, Dec. 13, 2018 Dep.
8	Excerpt of Jinping McCormick, Jan. 9, 2019 Dep.
9	Excerpt of Andrew Boyer, Jan. 15, 2019 Dep.
10	Excerpt of Christine Baeder, Jan. 24, 2019 Dep.
11	Excerpt of John Hassler, Nov. 16, 2018 Dep.
12	Declaration of Christine Baeder
13	Excerpt of Matthew Perri, April 24, 2019 Dep.
14	Excerpt of Expert Report of Dr. Edward Michna
15	Excerpt of Expert Report of Dr. Pradeep Chintagunta
16	Excerpt of Expert Report of Dr. Sean Nicholson
17	Excerpt of Expert Report of Dr. Melanie Rosenblatt
18	Excerpt of Kevin Vorderstrasse, Dec. 5, 2018 Dep.
19	Excerpt of Ginger Collier, Jan. 9, 2019 Dep.
20	Excerpt of Lisa Cardetti, Jan. 10, 2019 Dep.
21	FDA, “Generic Drugs: Questions & Answers,” available at <a href="https://www.fda.gov/drugs/questions-answers/generic-drugs-questions-answers">https://www.fda.gov/drugs/questions-answers/generic-drugs-questions-answers</a>
22	Supplemental Written Responses and Objection of Defendants’ Par Pharmaceutical, Inc. And Par Pharmaceutical Companies, Inc. To Plaintiffs’ Amended Notice Of Deposition Pursuant To Rule 30(B)(6) Nos. 4, 6-10, 13-16, 18, 22, 23, 37 and 39
23	Excerpt of George Stevenson, Feb. 15, 2019 Dep.